Chronic Urticaria Market Report and Forecast 2024-2032

The chronic urticaria market size is expected to grow at a CAGR of 8.7% during the forecast period of 2024-2032, driven by the development of novel drugs to mitigate the incidence of chronic urticaria across the globe.

Chronic Urticaria: Introduction

Chronic urticaria is a persistent skin condition characterized by the recurrent formation of itchy, raised, and often red welts or hives on the skin. These hives can last for six weeks or more and may recur frequently, causing discomfort and affecting daily life.

Unlike acute urticaria, which often results from allergies and subsides quickly, chronic urticaria can be triggered by various factors, including autoimmune disorders or underlying health conditions. Treatment typically involves antihistamines and, in some cases, identifying and managing potential underlying causes.

Key Trends in Chronic Urticaria Market

One of the primary trends is the rising prevalence of chronic urticaria globally. This condition affects a significant number of people, and this trend is driving the demand for treatments and medications.

There have been significant advancements in the treatment options available for chronic urticaria. This includes the development of new drugs, biologics, and therapies that aim to provide more effective and longer-lasting relief from symptoms.

Biologics, which are derived from living organisms, have shown promise in treating chronic urticaria. These include drugs that target specific immune system components involved in the condition. Immunomodulatory therapies have gained prominence in the treatment of chronic urticaria. This includes the use of monoclonal antibodies targeting specific pathways involved in the condition.

Tailoring treatments to individual patients based on their specific triggers and responses to therapy is becoming more common. Personalized medicine approaches aim to improve treatment outcomes and reduce side effects.

The adoption of telemedicine and digital health solutions has allowed patients to access healthcare professionals more easily, particularly in the management of chronic conditions like urticaria.

Chronic Urticaria Market Segmentation

Market Breakup by Drug Class

• Antihistamines
• H-2 Blockers
• Antidepressants
• Monoclonal Antibodies
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Market Breakup by -7MM

• United States
• EU-4 and the United Kingdom
• Japan

Chronic Urticaria Market Overview

The chronic urticaria market continues to experience growth due to the ongoing rise in the prevalence of the condition. This growth is expected to persist as awareness and diagnosis rates further improve. Tailoring treatments to individual patients based on specific triggers and responses to therapy is now a common practice, enhancing treatment outcomes.

Governments in various countries continue to launch public health campaigns aimed at increasing awareness about chronic urticaria, its symptoms, and the importance of early diagnosis and treatment. They have allocated research funding to better understand the underlying causes of chronic urticaria, with the aim of developing more effective treatments.

Government health agencies continue efforts to improve patient support networks and resources, aiding individuals in managing both the medical and psychosocial aspects of the condition.

Pharmaceutical giants remain actively engaged in mergers and acquisitions, expanding their product portfolios in the dermatology and allergy segments, including treatments for chronic urticaria. Major pharmaceutical companies such as Novartis, GSK, and Roche continue to compete to gain a larger market share by introducing innovative therapies. Smaller biotech enterprises that specialize in allergy and immunology continue to gain market share through the development of novel treatments.

Chronic Urticaria Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

The major companies in the market are as follows:

• Johnson & Johnson Private Limited
• Novartis AG
• Teva Pharmaceutical Industries Ltd
• Amneal Pharmaceuticals, Inc.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Ltd
• Dr. Reddy's Laboratories Ltd
• Mylan N.V
• GlaxoSmithKline plc
• Merck & Co., Inc.

The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.